July 30, 2026

EMBL spin-off Epitome Therapeutics launches to advance precision epigenome editing

EMBL spin-off Epitome Therapeutics launches to advance precision epigenome editing

The spin-off aims to develop a new generation of precision medicines using epigenome editing to precisely regulate gene expression without altering DNA

A newly launched EMBL spin-off, Epitome Therapeutics, aims to translate pioneering research in epigenome editing into a new generation of precision medicines. Co-founded by EMBL Group Leader Jamie Hackett, the company builds on cutting-edge research at EMBL Rome and will develop therapies that precisely regulate gene expression without altering the underlying DNA sequence.

The company’s proprietary CADENCE platform is based on research from the Hackett group at EMBL Rome, including discoveries published in Nature Genetics in 2024. The technology was exclusively licensed to Epitome Therapeutics through EMBLEM Technology Transfer GmbH (EMBLEM), EMBL’s wholly owned commercial arm and exclusive technology transfer partner. CADENCE represents a new approach to epigenome editing, enabling precise, durable, and tunable activation of gene expression.

While recent advances in gene editing have focused primarily on altering DNA sequences, many diseases actually result from genes being expressed at the wrong level rather than having the wrong sequence. Epitome Therapeutics is developing technologies designed to restore gene expression to therapeutically meaningful levels, creating opportunities to address diseases driven by dysregulated gene activity, including rare genetic and metabolic disorders.

“Genes do not need to be simply on or off – they need to be expressed at the right level,” said Jamie Hackett, EMBL Group Leader and co-founder of Epitome Therapeutics. “Our research has shown that epigenome editing can provide precise control over gene dosage, opening up the possibility of developing a new class of medicines that fine-tune gene activity rather than permanently altering the genome.”

The launch of Epitome Therapeutics reflects EMBL’s commitment to translating fundamental discoveries into societal impact. Through EMBLEM, EMBL supports researchers throughout the commercialisation journey: from protecting intellectual property and structuring spin-offs to securing early-stage validation funding, finding and building experienced leadership teams, and licensing technologies so that breakthroughs in fundamental research can ultimately benefit society at large.

Epitome Therapeutics was established with support from EMBLEM, which co-financed early validation of the CADENCE platform through the EMBL-GSK Young Entrepreneurs Award (co-funded with GSK), contributed to company formation, licensing, early-stage financing that leveraged additional funding, and continues to provide strategic support to the company.

“A cornerstone of successful spin-offs is excellent, ground-breaking science, but that alone is not enough. From company formation and intellectual property licensing to early validation funding and building the right leadership team, translating research into impact is a collaborative effort,” said Jürgen Bauer, Deputy Managing Director of EMBLEM.

The company has secured €4 million in initial funding through a combination of venture investment and competitive grant funding. The pre-seed round was co-led by XISTA Science Ventures and Caesar Ventures, with further participation from Navec Venture Holding GmbH and EMBLEM. Additional funding was secured through support from the Austrian federal development and financing bank AWS and the Austrian Research Promotion Agency (FFG).

This support will enable Epitome Therapeutics to further develop the CADENCE platform, expand its scientific team, and advance its first therapeutic programmes toward drug candidate selection.


Related links

Our latest News

discover more
2026 BioTech Breakthrough Honors VectorBuilder With “Overall CGT Solution Provider of the Year”

2026 BioTech Breakthrough Honors VectorBuilder With “Overall CGT Solution Provider of the Year”

Annual awards program recognizes innovation in life sciences and biotechnology worldwide CHICAGO, November 5, 2026 – VectorBuilder, a global leader in gene delivery technologies, today announced it has been named “Overall CGT Solution Provider of the Year” in the sixth annual BioTech Breakthrough Awards, recognizing innovation across the global life sciences and biotechnology industries. VectorBuilder integrates vector […]

Breast Milk for the Youngest Babies: New Milk Bank at Heidelberg University Hospital

Breast Milk for the Youngest Babies: New Milk Bank at Heidelberg University Hospital

The Heidelberg University Hospital (UKHD) recently launched “HeidelMilk,” a breast milk donation bank. It provides premature infants with donated breast milk when their own mothers’ milk supply is insufficient. To mark World Prematurity Day on November 15, the UKHD is introducing this new service. Full Text in German below. Muttermilch für die Kleinsten: Neue Milchbank […]

When Brake Cells Become Killer Cells: Double Honor for DKFZ Researcher Julius Michel

When Brake Cells Become Killer Cells: Double Honor for DKFZ Researcher Julius Michel

Julius Michel, a postdoctoral researcher at the German Cancer Research Center (DKFZ), has received two awards: the Craig Tendler Award for Myeloma Research from the American Society of Hematology – awarded for the first time and accompanied by a $10,000 prize – as well as another award from the society. He has discovered that a […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp